The prevailing predictive biomarkers for immunotherapy, mainly PD-L1 expression,7 tumor mutational burden (TMB),8 and molecular subtypes (SCLC-A, -N, -P, and -I),9,10 are far from satisfactory for SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.